Regeneron Pharmaceuticals (NASDAQ: REGN)
Regeneron Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Regeneron Pharmaceuticals Company Info
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
News & Analysis
Should You Sell This Stock Following a Regulatory Roadblock?
It's not the first such obstacle this high-performing drugmaker has faced.
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year.
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
These businesses are on paths to extremely bright futures.
Could Regeneron Stock Help You Retire a Millionaire?
The blossoming biotech might give more than a nudge to investors in this project.
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
These innovative biotechs likely aren't done rewarding their shareholders.
Where Will Regeneron Pharmaceuticals Be in 1 Year?
Can the stock continue its market-beating ways?
3 Stocks to Buy Before 2024 That Can Set You Up For Life
These stocks are still relatively cheap, but don't expect them to stay that way for long.
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
Regeneron has been an excellent investment in recent years. Can that trend continue?
Valuation
Podcast Episodes
Regeneron Stock Rose on COVID-19 Breakthrough
Regeneron Pharmaceuticals stock got a shot in the arm after it announced a possible drug candidate for coronavirus.
Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
3 Top Stocks After #ASH18
Positive trial data unveiled at the American Society of Hematology conference makes these top stocks to watch in 2019.
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.
Earnings Transcripts
Regeneron Pharmaceuticals Inc (REGN) Q3 2021 Earnings Call Transcript
REGN earnings call for the period ending September 30, 2021.
Regeneron Pharmaceuticals Inc (REGN) Q2 2021 Earnings Call Transcript
REGN earnings call for the period ending June 30, 2021.
Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript
REGN earnings call for the period ending March 31, 2021.
Regeneron Pharmaceuticals Inc (REGN) Q4 2020 Earnings Call Transcript
REGN earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.